Kurs
+4,51%
Likviditet
0,14 MSEK
Prenumeration
Kalender
Tid* | ||
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-19 | 08:00 | Bokslutskommuniké 2024 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-23 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2024-05-22 | - | Årsstämma |
2024-05-03 | - | Kvartalsrapport 2024-Q1 |
2024-02-22 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2023-05-24 | - | Årsstämma |
2023-05-03 | - | Kvartalsrapport 2023-Q1 |
2023-02-23 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-08-17 | - | Kvartalsrapport 2022-Q2 |
2022-05-25 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2022-05-24 | - | Årsstämma |
2022-04-29 | - | Kvartalsrapport 2022-Q1 |
2022-02-24 | - | Bokslutskommuniké 2021 |
2022-01-19 | - | Extra Bolagsstämma 2022 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-31 | - | Kvartalsrapport 2021-Q2 |
2021-06-03 | - | Extra Bolagsstämma 2021 |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-05-07 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2021-05-06 | - | Årsstämma |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-15 | - | Kvartalsrapport 2020-Q1 |
2020-05-07 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2020-05-06 | - | Årsstämma |
2020-02-21 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Extra Bolagsstämma 2019 |
2019-11-05 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2019-05-16 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2018-11-09 | - | Kvartalsrapport 2018-Q3 |
2018-08-31 | - | Kvartalsrapport 2018-Q2 |
2018-06-18 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2018-06-15 | - | Årsstämma |
2018-04-27 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-11-23 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-19 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2017-05-18 | - | Årsstämma |
2017-05-11 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-19 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2016-05-18 | - | Årsstämma |
2016-05-10 | - | Kvartalsrapport 2016-Q1 |
2016-02-16 | - | Bokslutskommuniké 2015 |
2015-11-10 | - | Kvartalsrapport 2015-Q3 |
2015-08-25 | - | Kvartalsrapport 2015-Q2 |
2015-06-04 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2015-06-03 | - | Årsstämma |
2015-05-28 | - | Kvartalsrapport 2015-Q1 |
2015-02-17 | - | Bokslutskommuniké 2014 |
2014-11-18 | - | Kvartalsrapport 2014-Q3 |
2014-08-19 | - | Kvartalsrapport 2014-Q2 |
2014-05-08 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2014-05-07 | - | Årsstämma |
2014-05-05 | - | Kvartalsrapport 2014-Q1 |
2014-02-18 | - | Bokslutskommuniké 2013 |
2013-11-27 | - | Kvartalsrapport 2013-Q3 |
2013-08-21 | - | Kvartalsrapport 2013-Q2 |
2013-05-06 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2013-05-03 | - | Årsstämma |
2013-04-24 | - | Kvartalsrapport 2013-Q1 |
2013-02-19 | - | Bokslutskommuniké 2012 |
2012-11-20 | - | Kvartalsrapport 2012-Q3 |
2012-08-21 | - | Kvartalsrapport 2012-Q2 |
2012-06-13 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
2012-06-12 | - | Årsstämma |
2012-05-22 | - | Kvartalsrapport 2012-Q1 |
2012-03-05 | - | Extra Bolagsstämma 2012 |
2012-02-09 | - | Bokslutskommuniké 2011 |
2011-10-17 | - | Kvartalsrapport 2011-Q3 |
2011-08-17 | - | Kvartalsrapport 2011-Q2 |
2011-06-01 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
AroCell has previously announced that they have signed a distribution agreement with Sub-Saharan Biomedical P.L.C. for the sale of TUBEX® TF in Ethiopia. Over the past few months, AroCell, together with its distributor, has been working on the local regulatory process and has now obtained regulatory approval for TUBEX® TF in Ethiopia.
Attaining regulatory approval is a challenging process but provides a competitive advantage once obtained.
After its launch in Africa, AroCell has focused on finding suitable distribution partners. The company has previously announced that it has signed agreements with distributors in Uganda, Ghana, and Kenya among others. These agreements involve the sale of the company's rapid test TUBEX® TF for typhoid fever.
"Ethiopia is a large country with 120 million inhabitants and a potentially important market for TUBEX® TF. It is gratifying that we have now accomplished the regulatory work," says Gunnar Wahlberg, Sales Manager for rapid tests at AroCell.
About AroCell
AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com